George S.

George Medicines is a late-stage biopharmaceutical company focused on developing innovative, single-pill, multi-mechanism combination therapies for the world's leading causes of death and disability, particularly cardiometabolic diseases. A spin-out from The George Institute for Global Health, the company leverages established clinical research to create proprietary low-dose combinations of existing medicines. Its lead candidate, Widaplik (GMRx2), is a triple-combination treatment for hypertension that recently received FDA approval. The company's strategy aims to improve patient adherence and clinical outcomes by simplifying complex treatment regimens into a single daily dose. George Medicines operates with a global footprint, maintaining offices in London, Sydney, and Melbourne.